<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068026</url>
  </required_header>
  <id_info>
    <org_study_id>HRC-GRA-17030-VBREATH-SH</org_study_id>
    <nct_id>NCT03068026</nct_id>
  </id_info>
  <brief_title>Influence of the VitaBreath on Exercise Tolerance in COPD</brief_title>
  <official_title>Influence of the VitaBreath Device on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Tyneside General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Tyneside General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with COPD have more air in their lungs than other people (this problem with high lung
      volumes is called &quot;hyperinflation&quot;). Unfortunately this is unhelpful as breathing at higher
      lung volumes requires more effort and contributes to breathlessness. When anyone exercises,
      they breathe more quickly. People with COPD have narrowed airways, which makes breathing out
      difficult. When they breathe more quickly they may not be able to breathe out fully before
      they need to take the next breath in. This means that the volume of air in their lungs tends
      to increase further during exercise, which makes breathing even more difficult. This problem
      is called &quot;dynamic hyperinflation&quot;.

      Pulmonary rehabilitation is one of the most helpful interventions for people with COPD and
      most of the benefit gained is from exercise. Anything that helps people increase the amount
      of exercise they can perform should lead to further improvements.

      Non-invasive positive pressure ventilation is a method of supporting a person's normal
      breathing. The ventilator delivers a flow of air at low pressure as you breathe out, which
      helps patients to breathe out more completely. The device also detects when patients start to
      breathe in and delivers a stronger flow of air at a higher pressure, helping them to take a
      deeper breath in. Previous research studies have shown that when people with COPD use
      non-invasive ventilation during exercise they are able to exercise for longer and are less
      breathless. The purpose of this study is to assess whether a new portable non-invasive
      ventilation device, called the VitaBreath, helps people with COPD recover from breathlessness
      during the exercise breaks more quickly (by reducing &quot;dynamic hyperinflation&quot;, described
      above) and to exercise for longer overall. The VitaBreath device is small and light, weighing
      0.5 kilograms (just over one pound). It is handheld and battery powered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with chronic obstructive pulmonary disease (COPD) dynamic hyperinflation (DH) and
      the concurrent mechanical constraints on tidal volume expansion during exercise increase work
      of breathing and perceived respiratory discomfort, limiting endurance. An additional
      consequence of DH and the concomitant high mean intrathoracic pressure swings, cardiac
      performance and, hence, supply of oxygenated blood to the malfunctioning peripheral muscles
      is further compromised. This contributes to perceived leg discomfort and exercise
      intolerance.

      Bronchodilator therapy is associated with a reduction in operating lung volumes, leading to
      improvements in perceived breathlessness and exercise tolerance. Heliox (helium and oxygen)
      is less dense and generates less airway resistance than air. Heliox breathing has been shown
      to improve exercise tolerance in COPD. A recent study demonstrated that compared to room air,
      breathing heliox during constant-load exercise (CLE) (continuous) increased inspiratory
      capacity (IC), and lessened DH, breathlessness and leg discomfort at isotime and at the point
      of exercise limitation. In addition, heliox breathing increased stroke volume, cardiac output
      and hence locomotor muscle oxygen delivery. However, the main drawback of heliox
      supplementation is the high cost, especially when it is used for long periods of time.
      Previous studies using inspiratory pressure support have shown improvements in dyspnoea and
      exercise capacity by reducing the work of breathing, as well as improved central hemodynamic
      responses and peripheral muscle oxygenation.

      In comparison to traditional noninvasive ventilators, the Vitabreath device, which provides
      positive inspiratory pressure, is compact, light and inexpensive. Ease of operation,
      portability and battery life support use to aid relief of breathlessness, including away from
      the patient's home. This should facilitate maintenance of, and improvement in, activity.
      Vitabreath may also prove to be a useful tool to increasing exercise tolerance and the
      intensity of training, and hence the magnitude of physiological adaptations by mitigating DH
      during rehabilitative exercise training.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized crossover trial. The two exercise modalities will be separately assessed in different groups of patients, but within each group the intervention (VitaBreath) will be compared to control (pursed-lip breathing).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise tolerance (total exercise time)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome is exercise tolerance (total exercise time) during continuous and interval exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>Breathlessness (assessed by Borg 1-10 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic hyperinflation</measure>
    <time_frame>12 months</time_frame>
    <description>Inspiratory capacity (Litres)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Continuous exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interval exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VitaBreath</intervention_name>
    <description>The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.</description>
    <arm_group_label>Continuous exercise</arm_group_label>
    <arm_group_label>Interval exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pursed Lip Breathing technique</intervention_name>
    <description>Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.</description>
    <arm_group_label>Continuous exercise</arm_group_label>
    <arm_group_label>Interval exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 40 years or older.

          2. Current or previous smoking history: 10 or more pack years.

          3. Spirometry confirmed stable COPD (GOLD stages II-IV) under optimal medical therapy.

          4. Exhibit substantial exercise-induced dynamic hyperinflation (Î”IC baseline &gt; 0,2 L)

        Exclusion Criteria:

          1. Orthopaedic, neurological or other concomitant diseases that significantly impair
             normal biomechanical movement patterns, as judged by the investigator.

          2. Moderate or severe COPD exacerbation within 6 weeks.

          3. Unstable cardiac arrhythmia.

          4. Unstable ischaemic heart disease, including myocardial infarction within 6 weeks.

          5. Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy.

          6. Uncontrolled hypertension.

          7. Uncontrolled hypotension (SBP&lt;85mmHg).

          8. Uncontrolled diabetes.

          9. Intolerance of the VitaBreath device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis Vogiatzis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northumbria University of Newcastle</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ioannis Vogiatzis, Professor</last_name>
    <phone>1913495446</phone>
    <email>ioannis.vogiatzis@northumbria.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Bourke, Doctor</last_name>
    <phone>01912934026</phone>
    <email>stephen.bourke@NHCT.nhs.uk</email>
  </overall_contact_backup>
  <reference>
    <citation>Vogiatzis I, Zakynthinos S. Factors limiting exercise tolerance in chronic lung diseases. Compr Physiol. 2012 Jul;2(3):1779-817. doi: 10.1002/cphy.c110015. Review.</citation>
    <PMID>23723024</PMID>
  </reference>
  <reference>
    <citation>O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Aug;160(2):542-9.</citation>
    <PMID>10430726</PMID>
  </reference>
  <reference>
    <citation>Louvaris Z, Vogiatzis I, Aliverti A, Habazettl H, Wagner H, Wagner P, Zakynthinos S. Blood flow does not redistribute from respiratory to leg muscles during exercise breathing heliox or oxygen in COPD. J Appl Physiol (1985). 2014 Aug 1;117(3):267-76. doi: 10.1152/japplphysiol.00490.2014. Epub 2014 Jun 5.</citation>
    <PMID>24903919</PMID>
  </reference>
  <reference>
    <citation>O'Donnell DE, Sanii R, Younes M. Improvement in exercise endurance in patients with chronic airflow limitation using continuous positive airway pressure. Am Rev Respir Dis. 1988 Dec;138(6):1510-4.</citation>
    <PMID>3059897</PMID>
  </reference>
  <reference>
    <citation>Keilty SE, Ponte J, Fleming TA, Moxham J. Effect of inspiratory pressure support on exercise tolerance and breathlessness in patients with severe stable chronic obstructive pulmonary disease. Thorax. 1994 Oct;49(10):990-4.</citation>
    <PMID>7974316</PMID>
  </reference>
  <reference>
    <citation>Bianchi L, Foglio K, Pagani M, Vitacca M, Rossi A, Ambrosino N. Effects of proportional assist ventilation on exercise tolerance in COPD patients with chronic hypercapnia. Eur Respir J. 1998 Feb;11(2):422-7.</citation>
    <PMID>9551748</PMID>
  </reference>
  <reference>
    <citation>Wysocki M, Meshaka P, Richard JC, Similowski T. Proportional-assist ventilation compared with pressure-support ventilation during exercise in volunteers with external thoracic restriction. Crit Care Med. 2004 Feb;32(2):409-14.</citation>
    <PMID>14758156</PMID>
  </reference>
  <reference>
    <citation>van 't Hul A, Gosselink R, Hollander P, Postmus P, Kwakkel G. Acute effects of inspiratory pressure support during exercise in patients with COPD. Eur Respir J. 2004 Jan;23(1):34-40.</citation>
    <PMID>14738228</PMID>
  </reference>
  <reference>
    <citation>Rodrigues MK, Oliveira MF, Soares A, Treptow E, Neder JA. Additive effects of non-invasive ventilation to hyperoxia on cerebral oxygenation in COPD patients with exercise-related O2 desaturation. Clin Physiol Funct Imaging. 2013 Jul;33(4):274-81. doi: 10.1111/cpf.12024. Epub 2013 Jan 21.</citation>
    <PMID>23692616</PMID>
  </reference>
  <reference>
    <citation>Ambrosino N, Cigni P. Non invasive ventilation as an additional tool for exercise training. Multidiscip Respir Med. 2015 Apr 9;10(1):14. doi: 10.1186/s40248-015-0008-1. eCollection 2015.</citation>
    <PMID>25874110</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 25, 2017</last_update_submitted>
  <last_update_submitted_qc>February 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northumbria University</investigator_affiliation>
    <investigator_full_name>Ioannis Vogiatzis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Non-invasive ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

